The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy

摘要: Introduction: Deregulated signaling pathways are associated with resistance to chemotherapy and endocrine treatment, providing a rationale for the implementation of novel targeted therapies in breast cancer therapy. Key molecules therapeutically ongoing clinical trials phosphoinositide 3-kinase-Akt-mammalian target rapamycin (mTOR), Src, insulin-like growth factor 1 receptor, heat shock protein-90, histone deacetylases, cyclin-dependent kinases (CDKs), Notch human epidermal receptors (HERs). Areas covered: This review provides an overview agents currently explored registered ClinicalTrials.gov. The main focus will be on their ability prevent or reverse chemoresistance cancer. Expert opinion: HER2 have extended survival substantially, both adjuvant metastatic setting, pointing crucial dependency this pathway HER2-amplified b...